Brief: Inmune Bio Inc says entered second amendment to exclusive license agreement to PITT agreement

Inmune Bio

20/04/2023 23:28

April 20 (Reuters) - INmune Bio Inc:
    * INMUNE BIO- UNDER SECOND PITT AMENDMENT REQUIREMENT TO
OBTAIN
MARKETING AUTHORIZATION FROM FDA OR FOREIGN EQUIVALENT FOR
PRODUCTS USING LICENSED TECHNOLOGY BY JUNE 26, 2031
    * INMUNE BIO INC - ON APRIL 17, ENTERED INTO ADDITIONAL
AMENDMENT
TO INKMUNE AGREEMENT TO REMOVE DUE DILIGENCE REQUIREMENTS OF
INKMUNE LICENSE AGREEMENT
    * INMUNE BIO INC - ON APRIL 17, ENTERED SECOND AMENDMENT TO
EXCLUSIVE LICENSE AGREEMENT TO PITT AGREEMENT
    * INMUNE BIO INC - UNDER SECOND PITT AMENDMENT DOSE OF FIRST
PATIENT IN A PHASE II CLINICAL TRIAL WOULD OCCUR BY JUNE 26,
2026

Further company coverage:  INMB.O 

 ((Reuters.Briefs@thomsonreuters.com;))